Celldex Therapeutics, Inc. (CLDX) Financial Statements
Industry: In Vitro & In Vivo Diagnostic Substances
In fiscal 2025, Celldex Therapeutics reported revenue of $1.5M, down 78.0% from $7.0M the year before. Net income was -$258.8M (a -16748.0% net margin), or -$3.90 per diluted share. Gross margin was 87.1% and operating margin was -18599.8%. Operating activities generated -$210.9M of cash, leaving -$213.6M of free cash flow. At fiscal year end, Celldex Therapeutics held $583.0M in total assets against $55.8M in total liabilities, including $28.9M of cash and equivalents.
Open the full interactive Celldex Therapeutics financials → Quarterly statements, key ratios, valuation history and price charts.
Celldex Therapeutics Key Stats
| Share Price | $28.25 |
|---|---|
| Market Cap | $2.20B |
| Revenue YoY Growth | -78.0% |
| 52-Week Range | $22.58 – $44.87 |
| Shares Outstanding | 77.8 million (basic, 2026 Q2) |
Celldex Therapeutics Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $7.4M | $4.7M | $2.4M | $6.9M | $7.0M | $1.5M |
| Cost of Goods Sold | $200,000 | $100,000 | $100,000 | $300,000 | $200,000 | $200,000 |
| Gross Profit | $7.2M | $4.6M | $2.3M | $6.6M | $6.8M | $1.3M |
| Operating Income | -$63.4M | -$71.2M | -$115.2M | -$154.5M | -$195.1M | -$287.4M |
| Pre-Tax Income | -$60.9M | -$70.7M | -$112.3M | -$141.4M | -$157.9M | -$258.8M |
| Income Tax | -$1.2M | -$227,000 | — | — | — | $0 |
| Net Income | -$59.8M | -$70.5M | -$112.3M | -$141.4M | -$157.9M | -$258.8M |
| Diluted EPS | -$2.02 | -$1.64 | -$2.40 | -$2.92 | -$2.45 | -$3.90 |
Celldex Therapeutics Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $0 | $120,000 | $15,000 | $22,000 |
| Net Income | -$67.0M | -$81.3M | -$78.7M | -$73.5M |
| Diluted EPS | -$1.01 | -$1.22 | -$1.18 | -$0.94 |
Celldex Therapeutics Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $43.8M | $39.1M | $29.4M | $34.8M | $28.4M | $28.9M |
| Current Assets | $197.8M | $410.8M | $317.7M | $431.7M | $747.2M | $534.7M |
| Total Assets | $235.8M | $444.7M | $352.7M | $465.6M | $792.3M | $583.0M |
| Current Liabilities | $14.2M | $16.5M | $18.6M | $31.1M | $39.5M | $51.0M |
| Total Liabilities | $26.5M | $25.2M | $26.5M | $36.5M | $45.3M | $55.8M |
| Shareholders' Equity | $209.4M | $419.5M | $326.2M | $429.2M | $747.0M | $527.2M |
Celldex Therapeutics Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | -$40.4M | -$60.9M | -$103.7M | -$107.3M | -$157.8M | -$210.9M |
| Cash From Investing | -$98.2M | -$216.2M | $89.9M | -$105.8M | -$290.1M | $209.1M |
| Cash From Financing | $171.2M | $272.4M | $4.1M | $218.5M | $441.4M | $2.4M |
| Free Cash Flow | -$42.0M | -$62.1M | -$105.5M | -$109.1M | -$159.7M | -$213.6M |
Figures from Celldex Therapeutics' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Celldex Therapeutics financials page for every line item.
Celldex Therapeutics Company Profile
| Ticker | CLDX |
|---|---|
| Exchange | Nasdaq |
| Industry | In Vitro & In Vivo Diagnostic Substances |
| Headquarters | Hampton, New Jersey |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Large accelerated filer |
| SEC CIK | 0000744218 |
Frequently Asked Questions
What was Celldex Therapeutics' revenue in fiscal 2025?
Celldex Therapeutics (CLDX) reported revenue of $1.5M for fiscal 2025.
What is Celldex Therapeutics' annual revenue history?
Celldex Therapeutics' annual revenue by fiscal year: 2020: $7.4M; 2021: $4.7M; 2022: $2.4M; 2023: $6.9M; 2024: $7.0M; 2025: $1.5M.
What was Celldex Therapeutics' net income in fiscal 2025?
Celldex Therapeutics reported net income of -$258.8M for fiscal 2025.
What was Celldex Therapeutics' earnings per share (EPS) in fiscal 2025?
Celldex Therapeutics' diluted EPS was -$3.90 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Celldex Therapeutics generate in fiscal 2025?
Celldex Therapeutics generated -$213.6M of free cash flow in fiscal 2025.
What was Celldex Therapeutics' revenue last quarter?
In its most recent reported quarter (2026 Q2), Celldex Therapeutics reported revenue of $22,000.
How many shares of Celldex Therapeutics are outstanding?
Celldex Therapeutics reported a weighted average of 77.8 million basic shares outstanding in 2026 Q2.
What is Celldex Therapeutics' market cap?
Based on its latest closing price, Celldex Therapeutics (CLDX) has a market capitalization of about $2.20B.
When does Celldex Therapeutics' fiscal year end?
Celldex Therapeutics' fiscal year end, as registered with the SEC, is December 31.
Where is Celldex Therapeutics headquartered?
Celldex Therapeutics lists its business address in Hampton, New Jersey in its SEC filings.
Celldex Therapeutics Competitors & Similar Companies
See all 15 In Vitro & In Vivo Diagnostic Substances companies →